Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 1 , Pages 19-26 , March 2006

Light dosimetry measurements during ALA-PDT of Barrett's oesophagus

  • M.R. Stringer

      Affiliations

    • Institute of Microwaves and Photonics, School of Electronic and Electrical Engineering, University of Leeds, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 113 3432095; fax: +44 113 3437265.
    • ,
  • C.J. Kelty

      Affiliations

    • Department of Surgery, Royal Hallamshire Hospital, Sheffield, UK
    • ,
  • R. Ackroyd

      Affiliations

    • Department of Surgery, Royal Hallamshire Hospital, Sheffield, UK
    • ,
  • S.B. Brown

      Affiliations

    • Centre for Photobiology and Photodynamic Therapy, School of Biochemistry and Microbiology, University of Leeds, UK

References 

  1. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982–993
  2. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol. 1997;92:1293–1297
  3. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118–124
  4. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888–1895
  5. Williamson WA, Ellis FH, Gibb SP, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg. 1990;49:537–541
  6. Brandt LJ, Blansky RL, Kauvar DR. Repeat laser therapy of recurrent Barrett's epithelium: success with anacidity. Gastrointest Endosc. 1995;41:267
  7. Barr H, Stone N, Rembacken B. Endoscopic therapy for Barrett's oesophagus. Gut. 2005;54:875–884
  8. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49:1–7
  9. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992;14:275–292
  10. Ackroyd R, Brown N, Vernon D, et al. 5-Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: a pharmacokinetic study. Photochem Photobiol. 1999;70:656–662
  11. Barr H, Tralau CJ, Boulos PB, et al. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury. Photochem Photobiol. 1987;46:795–800
  12. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo-controlled trial. Gut. 2000;47:612–617
  13. Wang KK, WongKeeSong LM, Nijhawan PK, et al. Does non-dysplastic Barrett's epithelium respond better to mucosal ablation?. Gastroenterology. 1998;114:A700
  14. Kelty CJ, Ackroyd R, Brown NJ. Comparison of high- vs. low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc. 2004;18:452–458
  15. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998;114:448–455
  16. Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus—a randomised controlled trial of photodynamic therapy (PDT) versus argon plasma coagulation (APC). Aliment Pharmacol Ther. 2004;20:1289–1296
  17. Okunaka T, Kato H, Conaka C, et al. Photodynamic therapy of esophageal carcinoma. Surg Endosc. 1990;4:150–153
  18. Overholt BF, DeNovo RC, Panjehpour M, Petersen MG. A centering balloon for photodynamic therapy of esophageal cancer tested in a canine model. Gastrointest Endosc. 1993;39:782–787
  19. Barr H, Shepherd NA, Dix T, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348:584–585
  20. Bays R, Wagnieres G, Robert D, et al. Light dosimetry for photodynamic therapy in the esophagus. Lasers Surg Med. 1997;20:290–303
  21. Lee CC, Pogue BW, Strawbridge RR, et al. Comparison of photosensitizer (AlPcS2) quantification techniques: in situ fluorescence microsampling versus tissue chemical extraction. Photochem Photobiol. 2001;74(3):453–460
  22. Diamond KR, Malysz PP, Hayward JE, Patterson MS. Quantification of fluorophore concentration in vivo, using two simple fluorescence-based measurement techniques. J Biomed Opt. 2005;10(2):1–10
  23. Star WM. Light dosimetry in vivo. Phys Med Biol. 1997;42:763–787
  24. Madsen SJ, Sun C-H, Tromberg BJ, Hirschberg H. Development of a novel indwelling balloon applicator for optimizing light delivery in photodynamic therapy. Lasers Surg Med. 2001;29:406–412
  25. Dimofte A, Zhu TC, Hahn SM, Lustig RA. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg Med. 2002;31:305–312
  26. Niedre MJ, Yu CS, Patterson MS, Wilson BC. Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid. Br J Cancer. 2005;92:298–304
  27. Van Staveren HJ, Beek JF, Ramaekers JWH, et al. Integrating sphere effect in whole bladder wall photodynamic therapy: I. 532nm versus 630nm optical irradiation. Phys Med Biol. 1994;39:947–959
  28. Hudson EJ, Stringer MR, Cairnduff F, et al. The optical properties of skin tumours measured during superficial photodynamic therapy. Lasers Med Sci. 1994;9:99–103
  29. König K, Schneckenburger H, Rück A, Steiner R. In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol B: Biol. 1993;18:287–290
  30. Sorensen R, Iani V, Moan J. Kinetics of photobleaching of nude mice exposed to different fluence rates of red light. Photochem Photobiol. 1998;68:835–840
  31. Robinson DJ, de Bruijn RS, van der Veen N, et al. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and fluence rate and the resulting biological effect. Photochem Photobiol. 1998;67(1):140–149
  32. Hudson EJ, Stringer MR, Van Staveren HJ, Smith MA. The development of radio-opaque, isotropic, fibre optic probes for light dosimetry studies in photodynamic therapy. Phys Med Biol. 1993;38:1529–1536
  33. Rotomskis R, Bagdonas S, Streckyte G. Spectroscopic studies of photobleaching and photoproduct formation of porphyrins used in phototherapy. J Photochem Photobiol B: Biol. 1996;33:61–67
  34. Bagdonas S, Ma L-W, Iani V, et al. Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol. 2000;72(2):186–192
  35. Collins P, Robinson DJ, Stringer MR, et al. The variable response of plaque psoriasis after a single treatment with topical 5-aminoleavulinic acid photodynamic therapy. Br J Dermatol. 1997;137:743–749
  36. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol. 1994;130(6):743–751
  37. Kriegmair M, Baumgartner R, Knuchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155(1):105–109

PII: S1572-1000(05)00155-9

doi: 10.1016/S1572-1000(05)00155-9

Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 1 , Pages 19-26 , March 2006

Article Tools

* Image Usage & Resolution